NCT01199562Active, not recruiting
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 153 (actual)
- First submitted
- 8 Sept 2010
- Start date
- 11 Jan 2011
- Primary completion date
- 30 Dec 2013
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, Amyloidosis, Myeloproliferative neoplasms, Follicular lymphoma, Hodgkin lymphoma, Chronic myeloid leukaemia, Myelodysplastic syndromes, Mantle cell lymphoma, Chronic lymphocytic leukaemia, Multiple myeloma, Acute myeloid leukemia
- NCT number
- NCT01199562
What you commit to
- Study type: Observational
- Participants enrolled: 153
- From 11 Jan 2011 to the primary completion date, 30 Dec 2013
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The recipient had prior polymerase chain reaction (PCR) positive CMV infection in blood or organ-specific disease in the past 12 months
- Concomitant anti-graft-versus-host disease (GVD) treatment includes in vivo T cell depletion
- No prior allogeneic HCT (Allo HCT) (autologous HCT \[Auto HCT\] is allowed)
Other illness
- Recipient is human immunodeficiency virus (HIV)-1 positive
Other
- The source of hematopoietic stem cells is T-cell depleted
Who the study is looking for
- Diagnosis: hematologic malignancies/disorders including aplastic anemia and myelodysplastic syndrome
- Procedure: first allogeneic, T cell-replete transplantation of stem-cells from peripheral blood or bone marrow of an human leukocyte antigen (HLA) matched, unrelated or nonsyngeneic sibling donor
- CMV seropositive donor and/or recipient
- Performance level: must have already been determined to be eligible for HCT at City of Hope (COH)
- Organ function requirements: The minimum organ function requirements should be the same as the requirements for HCT
- Informed Consent: All patients must be capable of signing a written informed consent and no consent can be provided by a legal guardian
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.